Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 452

2.

ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms.

Kuroda J, Kimura S, Andreeff M, Ashihara E, Kamitsuji Y, Yokota A, Kawata E, Takeuchi M, Tanaka R, Murotani Y, Matsumoto Y, Tanaka H, Strasser A, Taniwaki M, Maekawa T.

Br J Haematol. 2008 Jan;140(2):181-90. Epub 2007 Nov 20.

PMID:
18028486
3.

An inhibitor of Bcl-2 family proteins induces regression of solid tumours.

Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK, Kitada S, Korsmeyer SJ, Kunzer AR, Letai A, Li C, Mitten MJ, Nettesheim DG, Ng S, Nimmer PM, O'Connor JM, Oleksijew A, Petros AM, Reed JC, Shen W, Tahir SK, Thompson CB, Tomaselli KJ, Wang B, Wendt MD, Zhang H, Fesik SW, Rosenberg SH.

Nature. 2005 Jun 2;435(7042):677-81. Epub 2005 May 15.

4.

The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies.

Paoluzzi L, Gonen M, Bhagat G, Furman RR, Gardner JR, Scotto L, Gueorguiev VD, Heaney ML, Manova K, O'Connor OA.

Blood. 2008 Oct 1;112(7):2906-16. doi: 10.1182/blood-2007-12-130781. Epub 2008 Jun 30.

5.

B cell lymphoma-2 (BCL-2) homology domain 3 (BH3) mimetics demonstrate differential activities dependent upon the functional repertoire of pro- and anti-apoptotic BCL-2 family proteins.

Renault TT, Elkholi R, Bharti A, Chipuk JE.

J Biol Chem. 2014 Sep 19;289(38):26481-91. doi: 10.1074/jbc.M114.569632. Epub 2014 Aug 5.

6.

A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo.

Shoemaker AR, Oleksijew A, Bauch J, Belli BA, Borre T, Bruncko M, Deckwirth T, Frost DJ, Jarvis K, Joseph MK, Marsh K, McClellan W, Nellans H, Ng S, Nimmer P, O'Connor JM, Oltersdorf T, Qing W, Shen W, Stavropoulos J, Tahir SK, Wang B, Warner R, Zhang H, Fesik SW, Rosenberg SH, Elmore SW.

Cancer Res. 2006 Sep 1;66(17):8731-9.

7.

The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs.

High LM, Szymanska B, Wilczynska-Kalak U, Barber N, O'Brien R, Khaw SL, Vikstrom IB, Roberts AW, Lock RB.

Mol Pharmacol. 2010 Mar;77(3):483-94. doi: 10.1124/mol.109.060780. Epub 2009 Dec 28.

8.

Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo.

Kang MH, Kang YH, Szymanska B, Wilczynska-Kalak U, Sheard MA, Harned TM, Lock RB, Reynolds CP.

Blood. 2007 Sep 15;110(6):2057-66. Epub 2007 May 29.

9.

Design, synthesis, and activity evaluation of broad-spectrum small-molecule inhibitors of anti-apoptotic Bcl-2 family proteins: characteristics of broad-spectrum protein binding and its effects on anti-tumor activity.

Zheng CH, Yang H, Zhang M, Lu SH, Shi D, Wang J, Chen XH, Ren XH, Liu J, Lv JG, Zhu J, Zhou YJ.

Bioorg Med Chem Lett. 2012 Jan 1;22(1):39-44. doi: 10.1016/j.bmcl.2011.11.101. Epub 2011 Dec 1.

PMID:
22172701
10.

Inhibition of Bcl-2 and Bcl-X enhances chemotherapy sensitivity in hepatoblastoma cells.

Lieber J, Kirchner B, Eicher C, Warmann SW, Seitz G, Fuchs J, Armeanu-Ebinger S.

Pediatr Blood Cancer. 2010 Dec 1;55(6):1089-95. doi: 10.1002/pbc.22740.

PMID:
20680965
11.

[Progress in small-molecule inhibitors of Bcl-2 family proteins].

Tang Y, Zhang DY, Wu XM.

Yao Xue Xue Bao. 2008 Jul;43(7):669-77. Review. Chinese.

PMID:
18819468
12.

The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.

Witham J, Valenti MR, De-Haven-Brandon AK, Vidot S, Eccles SA, Kaye SB, Richardson A.

Clin Cancer Res. 2007 Dec 1;13(23):7191-8.

13.

Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins.

Tagscherer KE, Fassl A, Campos B, Farhadi M, Kraemer A, Böck BC, Macher-Goeppinger S, Radlwimmer B, Wiestler OD, Herold-Mende C, Roth W.

Oncogene. 2008 Nov 6;27(52):6646-56. doi: 10.1038/onc.2008.259. Epub 2008 Jul 28.

PMID:
18663354
14.

Structural biology of the Bcl-2 family of proteins.

Petros AM, Olejniczak ET, Fesik SW.

Biochim Biophys Acta. 2004 Mar 1;1644(2-3):83-94. Review.

15.

Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.

Simonin K, N'Diaye M, Lheureux S, Loussouarn C, Dutoit S, Briand M, Giffard F, Brotin E, Blanc-Fournier C, Poulain L.

Apoptosis. 2013 Apr;18(4):492-508. doi: 10.1007/s10495-012-0799-x.

PMID:
23344663
16.

Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells.

Mérino D, Khaw SL, Glaser SP, Anderson DJ, Belmont LD, Wong C, Yue P, Robati M, Phipson B, Fairlie WD, Lee EF, Campbell KJ, Vandenberg CJ, Cory S, Roberts AW, Ludlam MJ, Huang DC, Bouillet P.

Blood. 2012 Jun 14;119(24):5807-16. doi: 10.1182/blood-2011-12-400929. Epub 2012 Apr 26.

17.

Subversion of the Bcl-2 life/death switch in cancer development and therapy.

Adams JM, Huang DC, Strasser A, Willis S, Chen L, Wei A, van Delft M, Fletcher JI, Puthalakath H, Kuroda J, Michalak EM, Kelly PN, Bouillet P, Villunger A, O'Reilly L, Bath ML, Smith DP, Egle A, Harris AW, Hinds M, Colman P, Cory S.

Cold Spring Harb Symp Quant Biol. 2005;70:469-77.

PMID:
16869785
18.

Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737.

Oakes SR, Vaillant F, Lim E, Lee L, Breslin K, Feleppa F, Deb S, Ritchie ME, Takano E, Ward T, Fox SB, Generali D, Smyth GK, Strasser A, Huang DC, Visvader JE, Lindeman GJ.

Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2766-71. doi: 10.1073/pnas.1104778108. Epub 2011 Jul 18.

19.

Mitochondrial fragmentation and neuronal cell death in response to the Bcl-2/Bcl-x(L)/Bcl-w antagonist ABT-737.

Young KW, Piñón LG, Dhiraj D, Twiddy D, Macfarlane M, Hickman J, Nicotera P.

Neuropharmacology. 2010 Jun;58(8):1258-67. doi: 10.1016/j.neuropharm.2010.03.008. Epub 2010 Mar 20.

PMID:
20307556
20.

Targeting Bcl-2 family proteins in adult T-cell leukemia/lymphoma: in vitro and in vivo effects of the novel Bcl-2 family inhibitor ABT-737.

Ishitsuka K, Kunami N, Katsuya H, Nogami R, Ishikawa C, Yotsumoto F, Tanji H, Mori N, Takeshita M, Miyamoto S, Tamura K.

Cancer Lett. 2012 Apr 28;317(2):218-25. doi: 10.1016/j.canlet.2011.11.030. Epub 2011 Dec 2.

PMID:
22138435
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk